ArticleRadiation oncology (London, England)2026
Radionecrosis risk and local control after CyberKnife
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the prevention and treatment of radiation-induced brain necrosis: a narrative review.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic radiotherapy (SRT) is an effective treatment for patients with a limited number of brain metastases (BM). However, radionecrosis (RN) remains a concern, particularly in long-term survivors, as its distinction from tumor progression is challenging and may lead to inappropriate salvage strategies. Fractionated stereotactic radiotherapy (FSRT) has been proposed to improve the therapeutic ratio for larger lesions or postoperative cavities, but the optimal dose and fractionation remain uncertain. MATERIALS AND
methodsWe conducted a retrospective single-center study involving all consecutive patients who received SRT with CyberKnife® for BM between January 1, 2016, and December 31, 2023. Local control (LC) and RN were assessed on MRI according to RANO-BM criteria; RN was graded using CTCAE v5.0.
resultsA total of 131 patients with 197 BM were analyzed with a median follow-up of 41.7 months (range, 1.7–207.8). Median age was 63.4 years; lung cancer was the most common primary (70.2%). Most patients had a single BM (68.8%) and received treatment in the first-line metastatic setting (70.2%). At the lesion level (n = 197), most targets received 27 Gy in 3 fractions (52.3%) or 30 Gy in 5 fractions (45.7%). Crude LC was 85.3%, with 29 local failures. Larger BM was significantly associated with local failure (HR 1.03; 95% CI 1.01–1.05; p = 0.017). Median brain progression-free survival (bPFS) was 9.8 months (95% CI 7.4–13.6). Brain progression correlated with the initial number of BM (HR 1.41; 95% CI 1.10–1.8; p = 0.006). RN occurred in 42 patients (32.1%), symptomatic in 14.5% cases (11.4% grade 2, and 3.1% grade 3). Larger size of BM (HR 1.58; 95% CI 1.04–2.49; p = 0.048) and prior surgery (HR 2.12; 95% CI 1.05–4.33; p = 0.037) were independent predictors of RN.
conclusionFSRT achieved durable LC with acceptable rates of symptomatic RN in this cohort. Tumor volume and prior surgery were associated with both LC and RN, supporting individualized dose–fractionation strategies based on lesion size and clinical context. Further prospective data are needed to refine dose constraints and integrate evolving therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.